Is 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-? Is 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- safe for nursing mother and child? Does 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- extracts into breast milk? Does 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- has any long term or short term side effects on infants? Can 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- influence milk supply or can 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- decrease milk supply in lactating mothers?

When administered orally or intravenously, it is excreted into breast milk in clinically non-significant amount which is very lower than that prescribed to infants. This medication is authorized for use in infants older than 1 month of age. Be aware of the possibility of false negative results of bacterial cultures done to infants when the mother is on antibiotics, together with a higher risk of diarrheal disease due to imbalance of intestinal flora. When topically used with creams and vaginal ovules, absorption into serum is scanty, hence, excretion into breast milk is believed lower than that attained by systemic administration.

Amounts of 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- in milk are less than doses given to infants. Measurements of infant plasma levels during breastfeeding have not been reported. No studies have evaluated adverse effects of 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- on the infant during breastfeeding, but presumably they are similar to those of the closely related drug, metronidazole, such as increased risk of oral and rectal infections. As with metronidazole, concern has been raised about exposure of healthy infants to 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- via breastmilk,[1] because of possible mutagenicity and carcinogenicity. Opinions vary among experts on the advisability of using 1H-Imidazole, 1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro- during longer-term therapy while breastfeeding, but avoidance of breastfeeding for 3 days after a single dose should allow milk levels to drop to negligible values.[2] Other drugs are available for bacterial vaginosis, and can be given vaginally, which should result in lower amounts in breastmilk.